Technical Analysis for EDSA - Edesa Biotech, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 2.10 | -4.55% | -0.10 |
EDSA closed down 4.55 percent on Friday, November 15, 2024, on 64 percent of normal volume. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Closing Low | Bearish | 0.00% | |
| New 52 Week Low | Weakness | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Doji - Bullish? | Reversal | -4.55% | |
| New 52 Week Low | Weakness | -4.55% | |
| Outside Day | Range Expansion | -4.55% | |
| Wide Bands | Range Expansion | -4.55% | |
| Oversold Stochastic | Weakness | -4.55% | |
| New 52 Week Closing Low | Bearish | -4.55% |
| Alert | Time |
|---|---|
| Down 3% | 1 day ago |
| Fell Below Previous Day's Low | 1 day ago |
| Down 2 % | 1 day ago |
| Down 1% | 1 day ago |
| Up 1% | 1 day ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 12/13/2024
Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company focused on efficiently developing innovative treatments that address significant unmet medical needs. Edesa's lead product candidate, EB01, is a novel non-steroidal anti-inflammatory molecule (sPLA2 inhibitor) for the treatment of chronic allergic contact dermatitis which has demonstrated statistically significant improvements in multiple clinical studies. Edesa also intends to expand the utility of its sPLA2 inhibitor technology, which forms the basis for EB01, across multiple indications. The company is based in Toronto, Canada, with U.S. offices in Southern California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Medication Dermatitis
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Medication Dermatitis
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 6.46 |
| 52 Week Low | 2.09 |
| Average Volume | 26,770 |
| 200-Day Moving Average | 4.36 |
| 50-Day Moving Average | 3.76 |
| 20-Day Moving Average | 2.94 |
| 10-Day Moving Average | 2.42 |
| Average True Range | 0.28 |
| RSI (14) | 19.35 |
| ADX | 28.58 |
| +DI | 11.80 |
| -DI | 28.64 |
| Chandelier Exit (Long, 3 ATRs) | 3.44 |
| Chandelier Exit (Short, 3 ATRs) | 2.94 |
| Upper Bollinger Bands | 4.06 |
| Lower Bollinger Band | 1.82 |
| Percent B (%b) | 0.12 |
| BandWidth | 75.98 |
| MACD Line | -0.49 |
| MACD Signal Line | -0.43 |
| MACD Histogram | -0.0573 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 2.33 | ||||
| Resistance 3 (R3) | 2.35 | 2.29 | 2.29 | ||
| Resistance 2 (R2) | 2.29 | 2.24 | 2.28 | 2.27 | |
| Resistance 1 (R1) | 2.20 | 2.20 | 2.17 | 2.18 | 2.26 |
| Pivot Point | 2.14 | 2.14 | 2.13 | 2.13 | 2.14 |
| Support 1 (S1) | 2.05 | 2.09 | 2.02 | 2.03 | 1.94 |
| Support 2 (S2) | 1.99 | 2.05 | 1.98 | 1.93 | |
| Support 3 (S3) | 1.90 | 1.99 | 1.91 | ||
| Support 4 (S4) | 1.88 |
